Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 147

1.

DNA Vaccine-Induced Long-Lasting Cytotoxic T Cells Targeting Conserved Elements of Human Immunodeficiency Virus Gag Are Boosted Upon DNA or Recombinant Modified Vaccinia Ankara Vaccination.

Hu X, Valentin A, Cai Y, Dayton F, Rosati M, Ramírez-Salazar EG, Kulkarni V, Broderick KE, Sardesai NY, Wyatt LS, Earl PL, Moss B, Mullins JI, Pavlakis GN, Felber BK.

Hum Gene Ther. 2018 Sep;29(9):1029-1043. doi: 10.1089/hum.2018.065. Epub 2018 Jun 21.

2.

First-in-Human Randomized, Controlled Trial of Mosaic HIV-1 Immunogens Delivered via a Modified Vaccinia Ankara Vector.

Baden LR, Walsh SR, Seaman MS, Cohen YZ, Johnson JA, Licona JH, Filter RD, Kleinjan JA, Gothing JA, Jennings J, Peter L, Nkolola J, Abbink P, Borducchi EN, Kirilova M, Stephenson KE, Pegu P, Eller MA, Trinh HV, Rao M, Ake JA, Sarnecki M, Nijs S, Callewaert K, Schuitemaker H, Hendriks J, Pau MG, Tomaka F, Korber BT, Alter G, Dolin R, Earl PL, Moss B, Michael NL, Robb ML, Barouch DH; IPCAVD006/RV380/HIV-V-A002 Study Group.

J Infect Dis. 2018 Jul 13;218(4):633-644. doi: 10.1093/infdis/jiy212.

3.

Impact of a structured oculoplastic surgery rotation on specialist training in oral and maxillofacial surgery.

Payne K, Barnard N, Earl P, McVeigh K, Sen J.

Br J Oral Maxillofac Surg. 2018 May;56(4):351-352. doi: 10.1016/j.bjoms.2017.12.021. Epub 2018 Apr 5. No abstract available.

PMID:
29628169
4.

Intradermal HIV-1 DNA Immunization Using Needle-Free Zetajet Injection Followed by HIV-Modified Vaccinia Virus Ankara Vaccination Is Safe and Immunogenic in Mozambican Young Adults: A Phase I Randomized Controlled Trial.

Viegas EO, Tembe N, Nilsson C, Meggi B, Maueia C, Augusto O, Stout R, Scarlatti G, Ferrari G, Earl PL, Wahren B, Andersson S, Robb ML, Osman N, Biberfeld G, Jani I, Sandström E.

AIDS Res Hum Retroviruses. 2018 Feb;34(2):193-205. doi: 10.1089/AID.2017.0121. Epub 2017 Nov 27.

5.

Safety and Immunogenicity of PENNVAX-G DNA Prime Administered by Biojector 2000 or CELLECTRA Electroporation Device With Modified Vaccinia Ankara-CMDR Boost.

Ake JA, Schuetz A, Pegu P, Wieczorek L, Eller MA, Kibuuka H, Sawe F, Maboko L, Polonis V, Karasavva N, Weiner D, Sekiziyivu A, Kosgei J, Missanga M, Kroidl A, Mann P, Ratto-Kim S, Anne Eller L, Earl P, Moss B, Dorsey-Spitz J, Milazzo M, Laissa Ouedraogo G, Rizvi F, Yan J, Khan AS, Peel S, Sardesai NY, Michael NL, Ngauy V, Marovich M, Robb ML.

J Infect Dis. 2017 Nov 27;216(9):1080-1090. doi: 10.1093/infdis/jix456.

6.

Droplet digital PCR for rapid enumeration of viral genomes and particles from cells and animals infected with orthopoxviruses.

Americo JL, Earl PL, Moss B.

Virology. 2017 Nov;511:19-22. doi: 10.1016/j.virol.2017.08.005. Epub 2017 Aug 10.

7.

Preparation of Cell Cultures and Vaccinia Virus Stocks.

Cotter CA, Earl PL, Wyatt LS, Moss B.

Curr Protoc Protein Sci. 2017 Aug 1;89:5.12.1-5.12.18. doi: 10.1002/cpps.34.

PMID:
28762495
8.

Generation of Recombinant Vaccinia Viruses.

Wyatt LS, Earl PL, Moss B.

Curr Protoc Protein Sci. 2017 Aug 1;89:5.13.1-5.13.18. doi: 10.1002/cpps.33.

9.

Insufficient Innate Immunity Contributes to the Susceptibility of the Castaneous Mouse to Orthopoxvirus Infection.

Earl PL, Americo JL, Moss B.

J Virol. 2017 Sep 12;91(19). pii: e01042-17. doi: 10.1128/JVI.01042-17. Print 2017 Oct 1.

10.

Novel Nonreplicating Vaccinia Virus Vector Enhances Expression of Heterologous Genes and Suppresses Synthesis of Endogenous Viral Proteins.

Wyatt LS, Xiao W, Americo JL, Earl PL, Moss B.

mBio. 2017 Jun 6;8(3). pii: e00790-17. doi: 10.1128/mBio.00790-17.

11.

Preparation of Cell Cultures and Vaccinia Virus Stocks.

Cotter CA, Earl PL, Wyatt LS, Moss B.

Curr Protoc Mol Biol. 2017 Jan 5;117:16.16.1-16.16.18. doi: 10.1002/cpmb.33.

PMID:
28060410
12.

Generation of Recombinant Vaccinia Viruses.

Wyatt LS, Earl PL, Moss B.

Curr Protoc Mol Biol. 2017 Jan 5;117:16.17.1-16.17.18. doi: 10.1002/cpmb.32.

PMID:
28060405
13.

Three-Year Durability of Immune Responses Induced by HIV-DNA and HIV-Modified Vaccinia Virus Ankara and Effect of a Late HIV-Modified Vaccinia Virus Ankara Boost in Tanzanian Volunteers.

Joachim A, Munseri PJ, Nilsson C, Bakari M, Aboud S, Lyamuya EF, Tecleab T, Liakina V, Scarlatti G, Robb ML, Earl PL, Moss B, Wahren B, Mhalu F, Ferrari G, Sandstrom E, Biberfeld G.

AIDS Res Hum Retroviruses. 2017 Aug;33(8):880-888. doi: 10.1089/AID.2016.0251. Epub 2017 Jan 27.

14.

A homolog of the variola virus B22 membrane protein contributes to ectromelia virus pathogenicity in the mouse footpad model.

Reynolds SE, Earl PL, Minai M, Moore I, Moss B.

Virology. 2017 Jan 15;501:107-114. doi: 10.1016/j.virol.2016.11.010. Epub 2016 Nov 26.

15.

Generation of Recombinant Vaccinia Viruses.

Wyatt LS, Earl PL, Moss B.

Curr Protoc Microbiol. 2015 Nov 3;39:14A.4.1-14A.4.18. doi: 10.1002/9780471729259.mc14a04s39.

16.

Preparation of Cell Cultures and Vaccinia Virus Stocks.

Cotter CA, Earl PL, Wyatt LS, Moss B.

Curr Protoc Microbiol. 2015 Nov 3;39:14A.3.1-14A.3.18. doi: 10.1002/9780471729259.mc14a03s39.

17.

The effect of model inclination during fabrication on mouthguard calliper-measured and CT scan-assessed thickness.

Farrington T, Coward T, Onambele-Pearson G, Taylor RL, Earl P, Winwood K.

Dent Traumatol. 2016 Jun;32(3):192-200. doi: 10.1111/edt.12213. Epub 2015 Sep 23.

PMID:
26400727
18.

HIV-DNA Given with or without Intradermal Electroporation Is Safe and Highly Immunogenic in Healthy Swedish HIV-1 DNA/MVA Vaccinees: A Phase I Randomized Trial.

Nilsson C, Hejdeman B, Godoy-Ramirez K, Tecleab T, Scarlatti G, Bråve A, Earl PL, Stout RR, Robb ML, Shattock RJ, Biberfeld G, Sandström E, Wahren B.

PLoS One. 2015 Jun 29;10(6):e0131748. doi: 10.1371/journal.pone.0131748. eCollection 2015.

19.

An investigation into the relationship between thickness variations and manufacturing techniques of mouthguards.

Farrington T, Coward T, Onambele-Pearson G, Taylor RL, Earl P, Winwood K.

Dent Traumatol. 2016 Feb;32(1):14-21. doi: 10.1111/edt.12192. Epub 2015 Jun 11.

PMID:
26095259
20.

Potent functional antibody responses elicited by HIV-I DNA priming and boosting with heterologous HIV-1 recombinant MVA in healthy Tanzanian adults.

Joachim A, Nilsson C, Aboud S, Bakari M, Lyamuya EF, Robb ML, Marovich MA, Earl P, Moss B, Ochsenbauer C, Wahren B, Mhalu F, Sandström E, Biberfeld G, Ferrari G, Polonis VR.

PLoS One. 2015 Apr 14;10(4):e0118486. doi: 10.1371/journal.pone.0118486. eCollection 2015.

21.

Genetic studies of the susceptibility of classical and wild-derived inbred mouse strains to monkeypox virus.

Earl PL, Americo JL, Moss B.

Virology. 2015 Jul;481:161-5. doi: 10.1016/j.virol.2015.02.048. Epub 2015 Mar 17.

22.
23.

Elimination of A-type inclusion formation enhances cowpox virus replication in mice: implications for orthopoxvirus evolution.

Kastenmayer RJ, Maruri-Avidal L, Americo JL, Earl PL, Weisberg AS, Moss B.

Virology. 2014 Mar;452-453:59-66. doi: 10.1016/j.virol.2013.12.030. Epub 2014 Jan 29.

24.

Susceptibility of the wild-derived inbred CAST/Ei mouse to infection by orthopoxviruses analyzed by live bioluminescence imaging.

Americo JL, Sood CL, Cotter CA, Vogel JL, Kristie TM, Moss B, Earl PL.

Virology. 2014 Jan 20;449:120-32. doi: 10.1016/j.virol.2013.11.017. Epub 2013 Nov 28.

25.

Protective efficacy of a global HIV-1 mosaic vaccine against heterologous SHIV challenges in rhesus monkeys.

Barouch DH, Stephenson KE, Borducchi EN, Smith K, Stanley K, McNally AG, Liu J, Abbink P, Maxfield LF, Seaman MS, Dugast AS, Alter G, Ferguson M, Li W, Earl PL, Moss B, Giorgi EE, Szinger JJ, Eller LA, Billings EA, Rao M, Tovanabutra S, Sanders-Buell E, Weijtens M, Pau MG, Schuitemaker H, Robb ML, Kim JH, Korber BT, Michael NL.

Cell. 2013 Oct 24;155(3):531-9. doi: 10.1016/j.cell.2013.09.061. Epub 2013 Oct 24.

26.

Broad and potent cellular and humoral immune responses after a second late HIV-modified vaccinia virus ankara vaccination in HIV-DNA-primed and HIV-modified vaccinia virus Ankara-boosted Swedish vaccinees.

Nilsson C, Godoy-Ramirez K, Hejdeman B, Bråve A, Gudmundsdotter L, Hallengärd D, Currier JR, Wieczorek L, Hasselrot K, Earl PL, Polonis VR, Marovich MA, Robb ML, Sandström E, Wahren B, Biberfeld G.

AIDS Res Hum Retroviruses. 2014 Mar;30(3):299-311. doi: 10.1089/AID.2013.0149. Epub 2013 Nov 15.

27.

Return-to-play guidelines following facial fractures.

Fowell CJ, Earl P.

Br J Sports Med. 2013 Jul;47(10):654-6. doi: 10.1136/bjsports-2012-091697. Epub 2013 Feb 14.

PMID:
23410884
28.

Heterologous prime-boost regimens using rAd35 and rMVA vectors elicit stronger cellular immune responses to HIV proteins than homologous regimens.

Ratto-Kim S, Currier JR, Cox JH, Excler JL, Valencia-Micolta A, Thelian D, Lo V, Sayeed E, Polonis VR, Earl PL, Moss B, Robb ML, Michael NL, Kim JH, Marovich MA.

PLoS One. 2012;7(9):e45840. doi: 10.1371/journal.pone.0045840. Epub 2012 Sep 26.

29.

Immunization with multiple vaccine modalities induce strong HIV-specific cellular and humoral immune responses.

Hallengärd D, Applequist SE, Nyström S, Maltais AK, Marovich M, Moss B, Earl P, Nihlmark K, Wahren B, Bråve A.

Viral Immunol. 2012 Oct;25(5):423-32. doi: 10.1089/vim.2012.0046.

PMID:
23035853
30.

Lethal monkeypox virus infection of CAST/EiJ mice is associated with a deficient gamma interferon response.

Earl PL, Americo JL, Moss B.

J Virol. 2012 Sep;86(17):9105-12. doi: 10.1128/JVI.00162-12. Epub 2012 Jun 13.

31.

Inclusion of a CRF01_AE HIV envelope protein boost with a DNA/MVA prime-boost vaccine: Impact on humoral and cellular immunogenicity and viral load reduction after SHIV-E challenge.

Cox JH, Ferrari MG, Earl P, Lane JR, Jagodzinski LL, Polonis VR, Kuta EG, Boyer JD, Ratto-Kim S, Eller LA, Pham DT, Hart L, Montefiori D, Ferrari G, Parrish S, Weiner DB, Moss B, Kim JH, Birx D, VanCott TC.

Vaccine. 2012 Feb 27;30(10):1830-40. doi: 10.1016/j.vaccine.2011.12.131. Epub 2012 Jan 9.

32.

SIVmac239 MVA vaccine with and without a DNA prime, similar prevention of infection by a repeated dose SIVsmE660 challenge despite different immune responses.

Lai L, Kwa SF, Kozlowski PA, Montefiori DC, Nolen TL, Hudgens MG, Johnson WE, Ferrari G, Hirsch VM, Felber BK, Pavlakis GN, Earl PL, Moss B, Amara RR, Robinson HL.

Vaccine. 2012 Feb 21;30(9):1737-45. doi: 10.1016/j.vaccine.2011.12.026. Epub 2011 Dec 15.

33.

Broad and potent immune responses to a low dose intradermal HIV-1 DNA boosted with HIV-1 recombinant MVA among healthy adults in Tanzania.

Bakari M, Aboud S, Nilsson C, Francis J, Buma D, Moshiro C, Aris EA, Lyamuya EF, Janabi M, Godoy-Ramirez K, Joachim A, Polonis VR, Bråve A, Earl P, Robb M, Marovich M, Wahren B, Pallangyo K, Biberfeld G, Mhalu F, Sandström E.

Vaccine. 2011 Oct 26;29(46):8417-28. doi: 10.1016/j.vaccine.2011.08.001. Epub 2011 Aug 22.

34.

Prevention of infection by a granulocyte-macrophage colony-stimulating factor co-expressing DNA/modified vaccinia Ankara simian immunodeficiency virus vaccine.

Lai L, Kwa S, Kozlowski PA, Montefiori DC, Ferrari G, Johnson WE, Hirsch V, Villinger F, Chennareddi L, Earl PL, Moss B, Amara RR, Robinson HL.

J Infect Dis. 2011 Jul 1;204(1):164-73. doi: 10.1093/infdis/jir199.

35.

Partial efficacy of a VSV-SIV/MVA-SIV vaccine regimen against oral SIV challenge in infant macaques.

Marthas ML, Van Rompay KK, Abbott Z, Earl P, Buonocore-Buzzelli L, Moss B, Rose NF, Rose JK, Kozlowski PA, Abel K.

Vaccine. 2011 Apr 12;29(17):3124-37. doi: 10.1016/j.vaccine.2011.02.051. Epub 2011 Mar 4.

36.

A review of facial protective equipment use in sport and the impact on injury incidence.

Farrington T, Onambele-Pearson G, Taylor RL, Earl P, Winwood K.

Br J Oral Maxillofac Surg. 2012 Apr;50(3):233-8. doi: 10.1016/j.bjoms.2010.11.020. Epub 2011 Feb 3. Review.

PMID:
21295384
37.

Phase I safety and immunogenicity evaluation of MVA-CMDR, a multigenic, recombinant modified vaccinia Ankara-HIV-1 vaccine candidate.

Currier JR, Ngauy V, de Souza MS, Ratto-Kim S, Cox JH, Polonis VR, Earl P, Moss B, Peel S, Slike B, Sriplienchan S, Thongcharoen P, Paris RM, Robb ML, Kim J, Michael NL, Marovich MA.

PLoS One. 2010 Nov 15;5(11):e13983. doi: 10.1371/journal.pone.0013983.

38.

Preexisting vaccinia virus immunity decreases SIV-specific cellular immunity but does not diminish humoral immunity and efficacy of a DNA/MVA vaccine.

Kannanganat S, Nigam P, Velu V, Earl PL, Lai L, Chennareddi L, Lawson B, Wilson RL, Montefiori DC, Kozlowski PA, Moss B, Robinson HL, Amara RR.

J Immunol. 2010 Dec 15;185(12):7262-73. doi: 10.4049/jimmunol.1000751. Epub 2010 Nov 12.

39.

Identification of wild-derived inbred mouse strains highly susceptible to monkeypox virus infection for use as small animal models.

Americo JL, Moss B, Earl PL.

J Virol. 2010 Aug;84(16):8172-80. doi: 10.1128/JVI.00621-10. Epub 2010 Jun 2.

40.

Unravelling the concept of consumer preference: implications for health policy and optimal planning in primary care.

Foster MM, Earl PE, Haines TP, Mitchell GK.

Health Policy. 2010 Oct;97(2-3):105-12. doi: 10.1016/j.healthpol.2010.04.005. Epub 2010 May 14. Review.

PMID:
20466449
41.

Immunogenicity of viral vector, prime-boost SIV vaccine regimens in infant rhesus macaques: attenuated vesicular stomatitis virus (VSV) and modified vaccinia Ankara (MVA) recombinant SIV vaccines compared to live-attenuated SIV.

Van Rompay KK, Abel K, Earl P, Kozlowski PA, Easlick J, Moore J, Buonocore-Buzzelli L, Schmidt KA, Wilson RL, Simon I, Moss B, Rose N, Rose J, Marthas ML.

Vaccine. 2010 Feb 10;28(6):1481-92. doi: 10.1016/j.vaccine.2009.11.061. Epub 2009 Dec 6.

42.

A novel technique to secure the occlusal wafer during orthognathic surgery.

Abdelrahman A, Johnston C, Earl P, Opie N.

Br J Oral Maxillofac Surg. 2010 Jul;48(5):389-90. doi: 10.1016/j.bjoms.2009.10.024. Epub 2009 Nov 25. No abstract available.

PMID:
19939525
43.

Design and evaluation of multi-gene, multi-clade HIV-1 MVA vaccines.

Earl PL, Cotter C, Moss B, VanCott T, Currier J, Eller LA, McCutchan F, Birx DL, Michael NL, Marovich MA, Robb M, Cox JH.

Vaccine. 2009 Sep 25;27(42):5885-95. doi: 10.1016/j.vaccine.2009.07.039. Epub 2009 Aug 3.

44.

Recombinant Modified Vaccinia Ankara (MVA) effectively boosts DNA-primed HIV-specific immune responses in humans despite pre-existing vaccinia immunity.

Gudmundsdotter L, Nilsson C, Brave A, Hejdeman B, Earl P, Moss B, Robb M, Cox J, Michael N, Marovich M, Biberfeld G, Sandström E, Wahren B.

Vaccine. 2009 Jul 16;27(33):4468-74. doi: 10.1016/j.vaccine.2009.05.018. Epub 2009 May 29.

45.

Elucidating and minimizing the loss by recombinant vaccinia virus of human immunodeficiency virus gene expression resulting from spontaneous mutations and positive selection.

Wyatt LS, Earl PL, Xiao W, Americo JL, Cotter CA, Vogt J, Moss B.

J Virol. 2009 Jul;83(14):7176-84. doi: 10.1128/JVI.00687-09. Epub 2009 May 6.

46.

Long-term vaccine protection from AIDS and clearance of viral DNA following SHIV89.6P challenge.

Schell J, Rose NF, Fazo N, Marx PA, Hunter M, Ramsburg E, Montefiori D, Earl P, Moss B, Rose JK.

Vaccine. 2009 Feb 11;27(7):979-86. doi: 10.1016/j.vaccine.2008.12.017. Epub 2009 Jan 7.

47.

Broad immunogenicity of a multigene, multiclade HIV-1 DNA vaccine boosted with heterologous HIV-1 recombinant modified vaccinia virus Ankara.

Sandström E, Nilsson C, Hejdeman B, Bråve A, Bratt G, Robb M, Cox J, Vancott T, Marovich M, Stout R, Aboud S, Bakari M, Pallangyo K, Ljungberg K, Moss B, Earl P, Michael N, Birx D, Mhalu F, Wahren B, Biberfeld G; HIV Immunogenicity Study 01/02 Team.

J Infect Dis. 2008 Nov 15;198(10):1482-90. doi: 10.1086/592507.

48.

Rapid protection in a monkeypox model by a single injection of a replication-deficient vaccinia virus.

Earl PL, Americo JL, Wyatt LS, Espenshade O, Bassler J, Gong K, Lin S, Peters E, Rhodes L Jr, Spano YE, Silvera PM, Moss B.

Proc Natl Acad Sci U S A. 2008 Aug 5;105(31):10889-94. doi: 10.1073/pnas.0804985105. Epub 2008 Aug 4.

49.

Molecular epidemiology of human enterovirus 71 in the United Kingdom from 1998 to 2006.

Bible JM, Iturriza-Gomara M, Megson B, Brown D, Pantelidis P, Earl P, Bendig J, Tong CY.

J Clin Microbiol. 2008 Oct;46(10):3192-200. doi: 10.1128/JCM.00628-08. Epub 2008 Jul 23.

50.

Disparity between levels of in vitro neutralization of vaccinia virus by antibody to the A27 protein and protection of mice against intranasal challenge.

Fogg CN, Americo JL, Earl PL, Resch W, Aldaz-Carroll L, Eisenberg RJ, Cohen GH, Moss B.

J Virol. 2008 Aug;82(16):8022-9. doi: 10.1128/JVI.00568-08. Epub 2008 Jun 4.

Supplemental Content

Support Center